Medication info
Zadiplogin M Tablet 5/500 mg (Empagliflozin, Metformin Hydrochloride)

Zadiplogin M Tablet 5/500 mg (Empagliflozin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›5mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Youngpoong Pharmaceutical Co., Ltd.
Appearance
Orange-yellow, biconvex, oval film-coated tablet
Packaging
10 tablets/box (10 tablets/PTP x 1), 60 tablets/box (10 tablets/PTP x 6), 30 tablets/bottle, 60 tablets/bottle
Approval status
Active

MFDS item code 202201356 · Approved 2022.04.04 · Insurance code 661905720

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each active ingredient: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who do not achieve adequate glycemic control with metformin alone or in combination with other medicines, such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient’s current dose of metformin. If empagliflozin 10 mg (total daily dose) is well tolerated but additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this medicine from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive the same doses of empagliflozin and metformin that they were taking previously. When this medicine is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If a dose of this medicine is missed, take it as soon as remembered. However, do not take a double dose at one time; in this case, skip the missed dose. Special populations Patients with renal impairment No dose adjustment is necessary for patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should be initiated with the individual single-ingredient products, empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately (see Precautions for Use 2. Patients Who Must Not Take This Medicine, item 2)). Elderly patients In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.

Ingredients

Manufacturer
Youngpoong Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • abnormal blood sugar control
  • cardiovascular disease
  • cardiovascular events
View approved original text

This medication is used to assist in blood sugar control for adults with type 2 diabetes alongside dietary and exercise therapy. It is especially effective for patients whose blood sugar levels are not adequately controlled and can be administered to patients with cardiovascular disease. However, precautions related to cardiovascular events should be referred to professional guidelines. This improves blood sugar control and aids in diabetes management.

How to take

Adult dose

The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each active ingredient: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who do not achieve adequate glycemic control with metformin alone or in combination with other medicines, such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient’s current dose of metformin. If empagliflozin 10 mg (total daily dose) is well tolerated but additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this medicine from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive the same doses of empagliflozin and metformin that they were taking previously. When this medicine is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If a dose of this medicine is missed, take it as soon as remembered. However, do not take a double dose at one time; in this case, skip the missed dose. Special populations Patients with renal impairment No dose adjustment is necessary for patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should be initiated with the individual single-ingredient products, empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately (see Precautions for Use 2. Patients Who Must Not Take This Medicine, item 2)). Elderly patients In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.

Precautions

This medication is primarily used for treating diabetes. Rare side effects such as severe lactic acidosis can occur during administration, so particular caution is needed for patients with impaired kidney function or liver issues. Also, when taken with other diabetes medications such as insulin or sulfonylureas, hypoglycemic symptoms may appear, so blood sugar levels should be monitored closely. This medication should not be used in patients with moderate to severe renal impairment, acute infections, dehydration, heart failure, or acute myocardial infarction. It is necessary to stop taking this medication for a certain period before and after surgeries or tests using iodine contrast agents and resume after kidney function has returned to normal. It is safest for pregnant or breastfeeding women to avoid this medication. During use, symptoms such as urinary tract infections, genital infections, and increased urination may occur, and any irregular symptoms should be immediately reported to a physician. Additionally, this medication can cause reduced fluid volume and lower blood pressure; therefore, elderly individuals or those with hypotension need to be cautious during use. Long-term use can lead to decreased vitamin B12, so it's advisable to check vitamin B12 status. Alcohol consumption may increase the risk of lactic acidosis, so excessive drinking should be avoided while taking this medication. Patients should be well-informed about the symptoms of hypoglycemia, lactic acidosis, and ketoacidosis while on this medication and should inform medical staff immediately if symptoms occur. Finally, this medication is not recommended for children under 18 and should be administered to elderly patients at the minimum dose while regularly monitoring kidney function.

Side effects

  • Hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • constipation
Show 160 more
  • abnormal liver function tests
  • hepatitis
  • altered taste
  • itching
  • rash
  • hives
  • erythema nodosum
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • increased hematocrit
  • ketoacidosis
  • lactic acidosis
  • reduced fluid volume
  • perineal necrosis
  • vulvovaginitis
  • balanitis
  • asthenia
  • chest discomfort
  • chest pain
  • constipation
  • gastritis
  • dry mouth
  • gastrointestinal disturbances
  • oral discomfort
  • salivary gland pain
  • cerebral infarction
  • headache
  • sensory impairment
  • orthostatic dizziness
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • ischemic colitis
  • gastrointestinal bleeding
  • appendiceal abscess
  • appendicitis
  • chronic otitis media
  • peritonsillar abscess
  • pulmonary tuberculosis
  • sepsis
  • subcutaneous abscess
  • adnexal-ovarian abscess
  • vestibular neuritis
  • nasopharyngitis
  • upper respiratory tract infection
  • periodontitis
  • dental abscess
  • orthostatic vertigo
  • drowsiness
  • fatigue
  • peripheral edema
  • facial swelling
  • peripheral swelling
  • fever
  • facial edema
  • chills
  • strange sensation
  • edema
  • pain
  • puncture site pain
  • vascular stent stenosis
  • vascular stent thrombosis
  • weight loss
  • vulvar pruritus
  • genital pruritus
  • dyslipidemia
  • hyperglycemia
  • dermal cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • pityriasis alba
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal canal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal abrasion
  • glaucoma
  • macular fibrosis
  • eye discomfort
  • conjunctival congestion
  • pathological myopia
  • retinal detachment
  • retinal crystal bodies
  • retinal vein occlusion
  • macular retinal detachment
  • eyelid swelling
  • visual impairment
  • vitreous floater
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • exertional dyspnea
  • wet cough
  • allergic rhinitis
  • cough
  • skin laceration
  • rib fracture
  • iliotibial band syndrome
  • concussion
  • corneal abrasion
  • fall
  • hand fracture
  • iliotibial band syndrome
  • open eye injury
  • pelvic fracture
  • road traffic accident
  • splenic injury
  • sternum fracture
  • angina
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • tachycardia
  • atherosclerosis
  • deep vein thrombosis
  • diabetic vascular disorder
  • peripheral arterial occlusive disease
  • anxiety
  • depression
  • sleep disorders
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • hepatitis
  • otalgia
  • orthostatic vertigo
  • vertigo
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodule
  • unstable angina

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. It is crucial to maintain a storage temperature between 1 and 30 degrees Celsius at room temperature. Proper storage will ensure the medication's efficacy.

Appearance and packaging

Appearance

Orange-yellow, biconvex, oval film-coated tablet

Package unit

10 tablets/box (10 tablets/PTP x 1), 60 tablets/box (10 tablets/PTP x 6), 30 tablets/bottle, 60 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.